Lars Grundemar
Lars Grundemar
US$0.00
IPDD WG 1 Member, Structure-based drug design, LINXS Fellow
Lars Grundemar is an adjunct professor at Lund University and an experienced pharmaceutical executive. He obtained his PhD at the Department of Pharmacology, Lund University in 1991 and pursued research in the field of identification and characterization of G-protein coupled receptor for neuropeptide transmitters. Lars is also an MD and specialist in Clinical Pharmaology. He is currently the CEO for Oncorena, developing potential breakthrough therapy for metastatic renal cancer. Previously, Lars has held leadership R&D positions in global pharmaceutical corporations in Sweden, USA, Switzerland, Italy and Denmark.